Want to see AU:PHX full AI Analyst Report?
Top Page
PharmX Technologies
(Sydney:PHX)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.09
â–¼(-6.00% Downside)
Action:Reiterated
Date:09/18/26
The score is held down primarily by materially weaker 2026 operating performance (declining revenue, negative gross profit, and widening losses). Technical signals also indicate a persistent downtrend with weak momentum. These negatives are partially offset by a strong, low-leverage balance sheet and improved (but volatile) cash flow in 2026.
Positive Factors
Low leverage
Very low leverage gives PharmX greater financial flexibility than a heavily indebted business. Limited debt pressure can preserve cash for operations and investment, while reducing refinancing and interest burdens as management works to restore profitability over the next several quarters.
Negative Factors
Revenue contraction and gross loss
A sharp revenue decline combined with a negative gross margin indicates weaker commercial performance and reduced economic output from the business. Unless sales recover and gross profitability improves, PharmX may have less capacity to cover operating costs or invest in growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage gives PharmX greater financial flexibility than a heavily indebted business. Limited debt pressure can preserve cash for operations and investment, while reducing refinancing and interest burdens as management works to restore profitability over the next several quarters.
Read all positive factors
PharmX Technologies (PHX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$62.18M
Dividend Yield6.52%
Average Volume (3M)300.23K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth4.06%
EPS Growth-625.00%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryInformation Technology Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding668,618,650
10 Day Avg. Volume251,276
30 Day Avg. Volume300,226
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)3.46
Price to Sales (P/S)10.58
P/FCF Ratio100.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmX Technologies Business Overview & Revenue Model
Company Description
PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering and invoicing gateway; PharmX Marketplace, an e-commerce ordering ...
PharmX Technologies Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.62M | 7.32M | 6.49M | 6.02M | 11.92M |
| Gross Profit | -70.00K | 5.96M | 5.25M | 4.81M | 10.52M |
| EBITDA | -532.00K | 1.39M | 1.45M | 329.00K | 2.54M |
| Net Income | -1.83M | -264.00K | -1.77M | -1.05M | 252.00K |
Balance Sheet | |||||
| Total Assets | 27.27M | 18.82M | 29.86M | 36.52M | 30.77M |
| Cash, Cash Equivalents and Short-Term Investments | 2.57M | 4.17M | 13.14M | 12.81M | 5.76M |
| Total Debt | 540.00K | 894.00K | 240.00K | 32.00K | 326.00K |
| Total Liabilities | 3.99M | 2.90M | 13.88M | 14.31M | 7.57M |
| Stockholders Equity | 23.28M | 15.93M | 15.97M | 22.21M | 23.20M |
Cash Flow | |||||
| Free Cash Flow | 805.00K | -8.16M | 3.19M | 10.86M | 3.19M |
| Operating Cash Flow | 825.00K | -8.13M | 3.21M | 10.94M | 3.28M |
| Investing Cash Flow | -2.10M | -695.00K | 1.75M | -3.57M | -3.64M |
| Financing Cash Flow | -322.00K | -136.00K | -4.62M | -325.00K | -361.00K |
PharmX Technologies Technical Analysis
Positive
0.10
Price Trends
0.10
Positive
0.11
Negative
0.12
Negative
Market Momentum
>-0.01
Negative
58.40
Neutral
60.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PHX, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.10, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 58.40 is Neutral, neither overbought nor oversold. The STOCH value of 60.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PHX.
PharmX Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$148.48M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$15.02M | ― | -578.72% | ― | 113.42% | 29.17% | |
49 Neutral | AU$29.53M | -1.59 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$20.09M | -2.19 | -1688.04% | ― | 11.45% | 0.69% | |
46 Neutral | AU$62.18M | -24.62 | -9.39% | 6.52% | 4.06% | -625.00% | |
41 Neutral | AU$8.29M | -0.42 | -614.15% | ― | -46.09% | 70.70% |
* Healthcare Sector Average
AU:PHX
PharmX Technologies
0.10
-0.03
-26.15%
AU:BMT
Beamtree Holdings Ltd
0.10
-0.14
-58.33%
AU:AHE
MedAdvisor Limited
0.01
-0.03
-69.05%
AU:ALC
Alcidion Group Limited
0.11
<0.01
5.00%
AU:ICR
InteliCare Holdings Limited
0.02
>-0.01
-4.17%
AU:PCK
PainChek Ltd
0.10
-0.50
-83.90%
PharmX Technologies Corporate Events
PharmX Seeks ASX Quotation for 2.5 Million New Shares
Sep 29, 2026
PharmX Technologies Limited has applied for the quotation of 2,500,000 ordinary fully paid shares on the ASX, with an issue date of September 29, 2026. The new PHX securities have been issued under an employee incentive scheme, indicating the comp...
PharmX Technologies Issues 1.11 Million Unquoted Performance Rights Under Employee Incentive Plan
Sep 29, 2026
PharmX Technologies Limited has notified the market of the issue of 1,110,000 unquoted performance rights under its employee incentive scheme. The securities, which are subject to transfer restrictions and are not quoted on the ASX until those res...
PharmX Technologies Lapses 5.22 Million Performance Rights in Capital Update
Sep 29, 2026
PharmX Technologies Limited has notified the ASX of the cessation of 5,220,000 performance rights, which lapsed after the conditional rights to securities were not satisfied or became incapable of being met. The lapse of these performance rights r...
Pharmx Technologies to Outline FY26 Highlights at Coffee Microcaps Conference
Sep 22, 2026
Pharmx Technologies Limited will present at the Coffee Microcaps Sydney Conference on 22 September 2026, where CEO Tom Culver is scheduled to outline financial and commercial highlights from FY26 and update investors on the company’s progres...
PharmX Sets Key Dates for 2026 AGM as Growth Push Continues
Sep 21, 2026
PharmX Technologies has released the indicative timetable for its 2026 Annual General Meeting, setting 7 October 2026 as the final date for receiving new director nominations and confirming 25 November 2026 as the meeting date. The schedule signal...
PharmX Technologies Outlines FY26 Results with Strong Investor Disclaimers
Aug 27, 2026
PharmX Technologies has released an investor presentation outlining its FY26 results, positioning the document strictly as informational rather than an offer to buy or sell securities. The company stresses that the material is not a prospectus or ...
Pharmx Builds Momentum on Sigma Alliance and Marketplace Growth
Aug 26, 2026
Pharmx reported FY26 revenue of $7.7 million, up 3% year on year, with strong growth in recurring marketplace and analytics revenue but lower EBITDA of $1.1 million due to planned investment in its new Marketplace launch and the Sigma alliance. Gr...
PharmX Technologies Strengthens Governance Framework in Line with ASX Standards
Aug 26, 2026
PharmX Technologies has updated its corporate governance statement, confirming compliance in all material respects with the fourth edition of the ASX Corporate Governance Council’s principles and outlining the roles and responsibilities of t...
PharmX Technologies Posts Loss Despite Revenue Growth and Stronger Asset Base
Aug 26, 2026
PharmX Technologies Limited reported a 2.7% increase in revenues from ordinary activities to $7.7 million for the year ended 30 June 2026, while net profit attributable to owners plunged to a loss of $1.8 million, representing a sharp 591.7% deter...
PharmX Technologies Sets Date for 2026 Annual Results and Investor Webinar
Aug 20, 2026
PharmX Technologies Limited has scheduled the release of its annual report for the year ended 30 June 2026 on Thursday, 27 August 2026, underscoring a key disclosure event for investors in the ANZ pharmacy technology space. The timing signals the ...
PharmX Issues New Shares to Sigma Subsidiary Under Strategic Alliance
Jul 10, 2026
PharmX Technologies has issued 6,661,187 fully paid ordinary shares to CW Retail Holdings, a subsidiary of Sigma Healthcare, under the existing Strategic Alliance Agreement between the two companies. The issuance was undertaken without a prospectu...
PharmX Issues Additional Shares to Sigma Subsidiary, Strengthening Strategic Ties
Jul 10, 2026
PharmX Technologies Limited has issued 6,661,187 new fully paid ordinary shares to CW Retail Holdings Pty Ltd, a subsidiary of Sigma Healthcare, following the execution of a Deed of Amendment effective 10 July 2026. The issuance supplements an ini...
PharmX Technologies Confirms Sigma Healthcare’s 10% Strategic Stake
Jul 10, 2026
PharmX Technologies has completed the final step in its strategic alliance with Sigma Healthcare, confirming Sigma’s move to a full 10% shareholding in the pharma-tech company. Sigma initially subscribed for nearly 60 million shares, giving ...
Pharmx Secures Two-Year Renewal of Exclusive NDSS Agreement
Jul 6, 2026
Pharmx Technologies has renewed its long-standing exclusive agreement with Australia’s National Diabetes Services Scheme for a further 24 months starting 1 July 2026, cementing its status as critical digital infrastructure in the national he...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.